277 related articles for article (PubMed ID: 21862241)
1. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
Johanson CE; Arfken CL; di Menza S; Schuster CR
Drug Alcohol Depend; 2012 Jan; 120(1-3):190-5. PubMed ID: 21862241
[TBL] [Abstract][Full Text] [Related]
2. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
[TBL] [Abstract][Full Text] [Related]
4. Abuse and diversion of buprenorphine sublingual tablets and film.
Lavonas EJ; Severtson SG; Martinez EM; Bucher-Bartelson B; Le Lait MC; Green JL; Murrelle LE; Cicero TJ; Kurtz SP; Rosenblum A; Surratt HL; Dart RC
J Subst Abuse Treat; 2014 Jul; 47(1):27-34. PubMed ID: 24680219
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
[TBL] [Abstract][Full Text] [Related]
7. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.
Lofwall MR; Wunsch MJ; Nuzzo PA; Walsh SL
J Subst Abuse Treat; 2011 Oct; 41(3):321-9. PubMed ID: 21664789
[TBL] [Abstract][Full Text] [Related]
9. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
Arfken CL; Johanson CE; di Menza S; Schuster CR
J Subst Abuse Treat; 2010 Sep; 39(2):96-104. PubMed ID: 20598829
[TBL] [Abstract][Full Text] [Related]
10. Opioid dependence: rationale for and efficacy of existing and new treatments.
Fiellin DA; Friedland GH; Gourevitch MN
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
Koch AL; Arfken CL; Schuster CR
Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
13. Reimbursement and practice policies among providers of buprenorphine-naloxone treatment.
Wisniewski AM; Dlugosz MR; Blondell RD
Subst Abus; 2013; 34(2):105-7. PubMed ID: 23577902
[TBL] [Abstract][Full Text] [Related]
14. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Winstock AR; Lea T; Sheridan J
Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
[TBL] [Abstract][Full Text] [Related]
16. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
Negus SS
J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine for office-based treatment of patients with opioid addiction.
Manlandro JJ
J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
[TBL] [Abstract][Full Text] [Related]
18. The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone-experience from a medium-sized Finnish city.
Uosukainen H; Pentikäinen H; Tacke U
J Subst Abuse Treat; 2013 Jul; 45(1):143-7. PubMed ID: 23433750
[TBL] [Abstract][Full Text] [Related]
19. [Reimbursement of opiate substitution drugs to militaries in 2007].
d'Argouges F; Desjeux G; Marsan P; Thevenin-Garron V
Encephale; 2012 Sep; 38(4):304-9. PubMed ID: 22980471
[TBL] [Abstract][Full Text] [Related]
20. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
